Physician profile
Mazen E Hamad
NPI 1780606855
$6,526.39
in general payments reported to CMS, 2019-2025
42 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $342 · 2021: $1,097 · 2022: $754 · 2023: $961 · 2024: $1,101 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,319.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,526.14 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,201.55 | 2021-2025 | |
| Lilly USA, LLC | $853.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.06 | 2019-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $217.74 | 2019-2022 | |
| Glaxosmithkline, LLC. | $206.57 | 2019-2023 | Arexvy |
| Janssen Pharmaceuticals, INC | $201.26 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $194.00 | 2020-2021 | |
| Amgen INC. | $191.22 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $162.23 | 2019-2025 | |
| Abbott Laboratories | $148.92 | 2023-2025 | Proclaim, Eterna, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $146.48 | 2019-2022 | |
| Radius Health, INC. | $141.08 | 2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.40 | 2019-2023 | Synjardy, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.37 | 2025 | Caplyta |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $77.09 | 2021-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $63.60 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $62.18 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $56.72 | 2019-2024 | Airsupra |
| Bausch Health US, LLC | $54.89 | 2021-2023 | Wellbutrin, Aplenzin |
| Eisai INC. | $52.43 | 2022-2025 | |
| Medtronic, INC. | $52.31 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Currax Pharmaceuticals LLC | $46.02 | 2021-2025 | Contrave |
| Amarin Pharma, INC. | $42.68 | 2020-2021 | |
| Antares Pharma, INC. | $40.81 | 2019-2021 | |
| Ibsa Pharma INC. | $39.13 | 2022 | |
| Astellas Pharma US INC | $38.00 | 2023-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $35.70 | 2022 | |
| Idorsia Pharmaceuticals US INC | $35.69 | 2023-2024 | Quviviq |
| Insulet Corporation | $28.14 | 2023 | Omnipod |
| Angiodynamics, INC. | $22.85 | 2019 | |
| Exact Sciences Corporation | $19.80 | 2025 | The Cologuard Plus Collection Kit |
| Amneal Pharmaceuticals LLC | $17.32 | 2023 | Unithroid |
| Boston Scientific Corporation | $17.17 | 2020 | |
| Vanda Pharmaceuticals INC. | $16.78 | 2025 | Fanapt, Hetlioz |
| Genentech USA, INC. | $16.47 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.09 | 2022 | |
| Axonics, INC. | $15.07 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $13.73 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.06 | 2022 | |
| Mylan Specialty L.P. | $11.37 | 2019 | |
| Medtronic Minimed, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Hamad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.